CYP17A1 and prostate neoplasm: Abiraterone acetate is an androgen biosynthesis inhibitor, which can highly specifically and irreversibly bind to the rate limiting enzymes CYP17A1, C17 lyase, and C20 lyase for androgen synthesis, thereby inhibiting the androgen synthesis in testicular, adrenal, and prostate tumors [27].